Share and shareholders

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies.

The Company’s ordinary shares of no par value are only admitted to trading on the AIM market of the London Stock Exchange (FARN) from 17 November 2015 and on issuing Nasdaq First North Growth Market (FARON) from 3 December 2019.

Rights of Shareholders

Shareholders should note that the rights of shareholders in a company incorporated in Finland may be different from the rights of shareholders in a UK incorporated company.

Restrictions on the transferability of ordinary shares

There are no restrictions on the transfer of the Company´s AIM Securities.

Depositary issuing depositary interests
Computershare Investor Services PLC
The Pavilions
Bridgwater Road
Bristol BS13 8AE

The information above is disclosed in accordance with Rule 26 of the AIM Rules for Companies.